Biomedical Engineering Reference
In-Depth Information
181. Chen G et al (2002) 4-Hydroxytamoxifen sulfation metabolism. J Biochem Mol Toxicol
16:279-285
182. Nishiyama T et al (2002) Reverse geometrical selectivity in glucuronidation and sulfation of
cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sul-
fotransferases. Biochem Pharmacol 63:1817-1830
183. Falany JL et al (2006) Sulfation of raloxifene and 4-hydroxytamoxifen by human cytosolic
sulfotransferases. Drug Metab Dispos 34:361-368
184. Nowell S et al (2006) Pharmacogenetics of human cytosolic sulfotransferases. Oncogene
25:1673-1678
185. Lien EA et al (1988) Identification of 4-hydroxy-N-desmethyltamoxifen as a metabolite of
tamoxifen in human bile. Cancer Res 48:2304-2308
186. Lien EA et al (1989) Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen
metabolites in human biological fluids during tamoxifen treatment. Cancer Res 49:2175-2183
187. Kisanga ER et al (2005) Excretion of hydroxylated metabolites of tamoxifen in human bile
and urine. Anticancer Res 25:4487-4492
188. Ring A et al (2004) Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11:643-658
189. Hoskins J et al (2009) CYP2D6 And tamoxifen: DNA matters in breast cancer. Nat Rev
Cancer 9:576-586
190. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance:
part I. Clin Pharmacokinet 48:689-723
191. Zhou SF (2009) Polymorphism of human cytochrome P450 2D6 and its clinical significance:
part II. Clin Pharmacokinet 48:761-804
192. Lim HS et al (2007) Clinical implications of CYP2D6 genotypes predictive of tamoxifen
pharmacokinetics in metastatic breast cancer. J Clin Oncol 25:3837-3845
193. Gjerde J et al (2008) Effects of CYP2D6 and SULT1A1 genotypes including SULT1A1 gene
copy number on tamoxifen metabolism. Ann Oncol 19:56-61
194. Xu Y et al (2008) Association between CYP2D6 *10 genotype and survival of breast cancer
patients receiving tamoxifen treatment. Ann of Oncol Off J Eur Soc Med Oncol/ESMO
19:1423-1429
195. Kiyotani K et al (2010) Significant effect of polymorphisms in CYP2D6 and ABCC2 on
clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients. J Clin Oncol
28:1287-1293
196. Murdter TE et al (2011) Activity levels of tamoxifen metabolites at the estrogen receptor and
the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels
in plasma. Clin Pharmacol Ther 89:708-717
197. Goetz MP et al (2005) Pharmacogenetics of tamoxifen biotransformation is associated with
clinical outcomes of efficacy and hot flashes. J Clin Oncol 23:9312-9318
198. Goetz MP et al (2007) The impact of cytochrome P450 2D6 metabolism in women receiving
adjuvant tamoxifen. Breast Cancer Res Treat 101:113-121
199. Schroth W et al (2007) Breast cancer treatment outcome with adjuvant tamoxifen relative to
patient CYP2D6 and CYP2C19 genotypes. J Clin Oncol 25:5187-5193
200. Kiyotani K et al (2008) Impact of CYP2D6*10 on recurrence-free survival in breast cancer
patients receiving adjuvant tamoxifen therapy. Cancer Sci 99:995-999
201. Newman WG et al (2008) Impaired tamoxifen metabolism reduces survival in familial breast
cancer patients. Clin Cancer Res 14:5913-5918
202. Schroth W et al (2009) Association between CYP2D6 polymorphisms and outcomes among
women with early stage breast cancer treated with tamoxifen. JAMA 302:1429-1436
203. Bijl MJ et al (2009) The CYP2D6*4 polymorphism affects breast cancer survival in tamox-
ifen users. Breast Cancer Res Treat 118:125-130
204. Ramon y Cajal T et al (2010) Impact of CYP2D6 polymorphisms in tamoxifen adjuvant
breast cancer treatment. Breast Cancer Res Treat 119:33-38
205. Serrano D et al (2011) Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and
SULT1A1 genotype in the Italian tamoxifen prevention trial. Pharmacogenomics J 11:100-107
